Nine selected isolates of Candida albicans were tested for their susceptibilities to amphotericin B and fluconazole by using three methods to assess the effect of incubation time and buffer concentration. By using a microdilution method with 0.0165 M 3-(N-morpholino)propanesulfonic acid (MOPS) and a 24-h incubation time, all of the isolates were found to be susceptible to amphotericin B and fluconazole. After 48 h of incubation, all isolates were still susceptible to amphotericin B. Seven of the nine isolates were resistant to fluconazole, and for the remaining two isolates, MICs increased by fourfold or more but the isolates remained susceptible (MIC, <10 g/ml). 
A steady increase in the number of fungal infections has been seen in medical centers, such as ours, that care for immunocompromised patients, including those with AIDS (4) . A 487% increase in Candida sp. bloodstream infection was reported in the United States between 1980 and 1989 by the National Nosocomial Infections Surveillance System (13) . According to Johnson and Warnock (9) , 80% of AIDS patients are at some time diagnosed with oral candidiasis. The infection is usually difficult to eradicate completely, with patients receiving antifungal agents continuously or intermittently for long periods of time. This type of drug therapy may lead to resistance (7) , and reliable in vitro susceptibility testing can be useful for selecting subsequent antifungal therapy.
Commonly used systemic antifungal agents include amphotericin B, flucytosine, ketoconazole, fluconazole, and itraconazole. Several factors inherent in these drugs have made fungal susceptibility tests difficult to develop and standardize. Amphotericin B is light and heat sensitive and is poorly soluble in water. Flucytosine must be used only with synthetic media because purine and pyrimidine bases can antagonize its activity (15) . The azoles are relatively broad spectrum antifungal agents, but only fluconazole has good water solubility. In addition, azoles are considered fungistatic compounds that may lead to a poorly defined endpoint in susceptibility tests (15) . Test conditions such as incubation time, buffer concentration, pH, inoculum size, and endpoint determination criteria significantly affect results, making the reproducibility of susceptibility tests problematic (1, 3, 12, 15) . In response, the National Committee for Clinical Laboratory Standards (NCCLS) has proposed a broth macrodilution standard that defines these parameters (10) . Unfortunately, with all of the antifungal agents available, broth macrodilution tests are expensive, timeconsuming, and tedious to perform. Therefore, we have developed a broth microdilution test that is in routine use at our institution. The test is based on the initial proposed guidelines (8) . We evaluated 50 strains of Candida albicans as part of a study searching for azole resistance in archived isolates and found nine isolates for which the results obtained with at least one antifungal agent were significantly affected by incubation time. Using these nine selected clinical isolates of C. albicans, we compared the NCCLS broth macrodilution method, using the tentative guidelines of NCCLS, to our broth microdilution method (in which we evaluated the results at 24 and 48 h) and a modified broth macrodilution method. For the last two test methods we used 0.0165 M 3-(N-morpholino)propanesulfonic acid (MOPS), which is 1/10 the concentration recommended by NCCLS. This 0.0165 M concentration of MOPS was selected on the basis of our earlier work (8) .
(This work was presented in part at the 96th General Meeting of the American Society for Microbiology, New Orleans, La., 19 to 23 May 1996 [15a] .)
MATERIALS AND METHODS
Fifty historical clinical isolates of C. albicans were initially tested by a broth microdilution method as reported by Hacek and colleagues (8) . The dilution micromethod is a modification of the method recommended by NCCLS in its tentative standard guidelines, but a lower MOPS buffer concentration than that recommended by NCCLS is used. Microtiter trays (panels) were prepared with two different types of culture media: Eagle's minimal essential medium (BioWhittaker, Walkersville, Md.) and RPMI 1640 medium (Bio-Whittaker), into both of which 0.0165 M MOPS buffer was incorporated. Each medium contained six antifungal agents (amphotericin B, flucytosine, fluconazole, ketoconazole, itraconazole, and miconazole). All antifungal drugs were obtained as reference material from their respective manufacturers. Two trays were inoculated for each isolate. One tray was incubated at 30°C, and the other was incubated at 35°C. Readings were taken at 24 and 48 h. Among this initial group of isolates, we found nine for which the interpretation of the results changed from susceptible to resistant for at least one of the drugs from the 24-h to the 48-h reading. Fluconazole was the only agent whose MIC changed for all of these isolates. To further investigate this observation, the nine isolates were tested by two broth macrodilution methods with fluconazole and amphotericin B.
The broth macrodilution test was performed by using the NCCLS tentative standard reference method for broth dilution antifungal susceptibility testing of yeasts, except that the buffer concentration was altered in one set of experiments (10) . A 0.165 M concentration MOPS buffer recommended by NCCLS was tested along with a 0.0165 M concentration (1/10 of the concentration proposed by NCCLS). Stock solutions of the antifungal agents were made in accordance with the tentative standard. The stock solutions (1,000 g/ml) were prepared, divided into aliquots, and stored at Ϫ80°C. A new aliquot was thawed on each day of use. Isolates were tested, in duplicate, against amphotericin B that was serially diluted to 0.5, 1.0, 2.0, and 4.0 g/ml and fluconazole that was serially diluted to concentrations of 2.5, 5.0, 10.0, and 20.0 g/ml, the same concentrations used with the microtiter test panels. These two agents are the focus of this report and the only ones selected for use in the comparison of the broth macrodilution test with the microdilution test. The concentrations of the other agents in the microtiter trays were those described previously (8) .
Prior to use, the isolates had been stored in sterile water at room temperature for various periods of time. Before testing, each isolate was subcultured twice onto Sabouraud dextrose agar (Emmons) plates, and the plates were incubated for 18 to 24 h at 35°C to ensure their capacity for active growth. A direct suspension of the organism was prepared from the second plate in sterile 0.85% saline so that its turbidity matched that of a 0.5 McFarland standard. It was then inoculated into RPMI 1640 broth containing the previously described concentrations of fluconazole or amphotericin B along with 0.024 M NaHCO 3 and either 0.165 or 0.0165 M MOPS buffer. The final inoculum density in each tube was 0.5 ϫ 10 3 to 2.5 ϫ 10 3 CFU/ml. The tubes were incubated in air at 35°C without agitation for 48 h.
The growth in each well or tube was graded on a four-point scale, with ϩ2 being maximum growth equaling the amount of growth in the control well or tube. Growth approximating 50% of the control growth was called ϩ1, and trace or trailing (Tr) was considered any growth of Յ10% of the growth in the well or tube with ϩ2 growth. Negative growth corresponded to no visible growth in the well or tube. Wells or tubes in which growth was between Tr and ϩ1 were graded as belonging to the group whose growth they matched most closely (Tr or ϩ1). Trace growth was occasionally seen in several wells or tubes and was defined as a trailing endpoint that was ignored when determining the MIC. This approach approximates the 80% growth cutoff recommended by NCCLS (10) .
Colony counts were performed by subculturing 0.01 ml from a growth control well or tube at the time of inoculation onto blood agar and inhibitory mold agar plates as a check for purity and inoculum density. An uninoculated control tube or well was also run in tests with each isolate to ensure broth sterility. One of the following control strains from the American Type Culture Collection (ATCC; Rockville, Md.) was tested weekly with each set of experiments: Candida albicans ATCC 90028 Candida parapsilosis ATCC 22019, or Candida krusei ATCC 6258.
RESULTS
The initial susceptibility results for the nine isolates tested by the broth microdilution method that differed between 24 and 48 h of incubation are presented in Table 1 . All nine of the isolates remained susceptible to amphotericin B in both the broth microdilution susceptibility tests and the broth macrodilution susceptibility tests, regardless of the test method. However, when tested against fluconazole, various results were obtained for these nine strains when the results obtained with the two buffer concentrations were compared. Table 2 summarizes these results. Additionally, we found that the problem of trailing endpoints for fluconazole was affected by both the buffer concentrations as well as the two incubation times studied. The year of recovery for each strain is included in Table 2 , indicating that most strains were isolated from clinical specimens prior to the introduction of the use of fluconazole at our medical center in 1992. The longer incubation time and the higher buffer concentration were also each accompanied by a greater likelihood for a trailing endpoint to occur. A trailing endpoint was seen with three of the nine strains in the 24-h broth microdilution test and the 48-h broth macrodilution test with 0.0165 M MOPS buffer. However, the 48-h broth microdilution test showed trailing for seven of nine strains, and all nine strains demonstrated a trailing effect when the 48-h broth macrodilution method with 0.165 M MOPS buffer was used.
The results of all duplicate tests agreed within 1 dilution. When the paired tests were not identical, the more resistant doubling dilution was recorded as the result. The three control strains performed as expected.
DISCUSSION
An issue that clinical laboratories must address when they are faced with implementing a new test such as antifungal susceptibility testing is the reproducibility of the method for determination of susceptibility or resistance. In this study we investigated technical factors that could affect reproducibility and influence the level of sensitivity to fluconazole, as determined by our laboratory method. The data indicate that for several strains of C. albicans (9 of 50 strains; 18%) there appears to be an increase in resistance in vitro when comparing results obtained by tests with 48-h versus 24-h incubation times. The same phenomenon of altered susceptibility in these strains was observed when comparing the results obtained with a 0.165 M MOPS buffer concentration with those obtained with a buffer concentration that was only 10% of that level. There is support for our findings of surprising fluconazole resistance in early archived strains used in the original test that was done for the development of the tentative NCCLS method. Espinel-Ingroff et al. (5) found that the fluconazole MIC for anywhere from 25 to 75% of the 35 C. albicans strains tested was 128 g/ml, depending on how the endpoint was read. While the initial isolation date of these strains was not noted, it is likely that they were from the same historical period as our isolates. With this in mind, the original report (5) also seemed to lean toward showing considerable resistance in the strains tested when none should be expected. The results found by Sewell and associates (14) are also consistent with our results when they are carefully examined. They observed that fluconazole MICs for 122 C. albicans were markedly higher at 48 h than the results obtained at 24 h by the broth microdilution method when the exact tentative NCCLS method was used. The endpoints that they found showed that 100% of strains were sensitive to 2 g of fluconazole per ml at 24 h by the microdilution method. This rose to Ͼ256 g/ml to encompass 100% of strains at 48 h by both the macrodilution and the microdilution tests. It is unknown what percentage of isolates had this marked shift, but it was likely significant since the MIC at which 50% of isolates are inhibited (MIC 50 ) also doubled when the incubation time went from 24 to 48 h. For their microdilution test, the MIC 50 at 24 h was 0.25 g/ml and the MIC 90 was 0.5 g/ml, with an MIC range of from 0.12 to 2.0 g/ml. The NCCLS macrodilution method that they followed, in which the results were read at 48 h, provided a fluconazole MIC 50 of 0.5 g/ml and an MIC 90 of 1 g/ml, with a range of MICs of from 0.12 to Ͼ256 g/ml. When 48-h microdilution results were compared to the results of the standard NCCLS method, there was good agreement between the two methods, which is consistent with our data.
Incubation time is one of the many factors that influence fungal susceptibility tests. Due to the relatively slow growth rates of yeasts and fungi compared to those of bacteria, a 48-h incubation time could be necessary. In our study, a result that demonstrated susceptibility to one that demonstrated resistance was frequently observed for azoles, particularly fluconazole, with the selected strains, but this was not observed when testing amphotericin B. When we tested our strains against fluconazole by the broth microdilution tests, the MICs for seven (78%) of the nine selected isolates tested increased, resulting in a change in the interpretation to resistance when incubation was increased from 24 to 48 h (Table 2) . Similar results were found by Sheehan and coworkers (15) . In their review they found that lengthening of the incubation time has little effect on the activity of amphotericin B, but it consistently raises the MICs of the azole agents tested. We found that the problem of a trailing endpoint, which made the precise determination of a MIC more difficult, was also increased by use of 48-h incubation and the higher, currently recommended MOPS buffer concentration. This occurred in both the microand macrodilution tests. Azoles are known to be fungistatic and not fungicidal drugs (15) . Therefore, an increase in the MIC at 48 h is not wholly unexpected. However, this phenomenon can lead to the reporting of false resistance to these antimicrobial agents.
The other influential factor in fungal susceptibility that we investigated was buffer concentration. We compared the current concentration recommended by NCCLS (0.165 M MOPS) to a level 1/10 of that recommended by NCCLS. The higher buffer concentration resulted in a finding of resistance for all nine of our susceptible isolates. A similar tendency was noted in a previous study by Hacek et al. (8) . Werner et al. (16) also reported that the presence of MOPS increased the resistance by up to 6 dilutions in some of their tests. A hypothesis to explain this phenomenon is that a lower MOPS concentration permits more rapid growth of the yeast in those wells where they are not inhibited by the antifungal agent. The faster growth, we believe, is facilitated by not maintaining the broth medium so close to pH 7.0 after growth begins, but rather permitting a fall in pH that many yeasts appear to prefer. Beggs and Hughes (2) provided support for this concept. They incubated C. albicans in pH 7.0 broth medium for 3 h and then demonstrated that the strain grew 0.5 log 10 more when the pH of the broth was reduced to 5.5 for the next 6 h than when it was maintained at pH 7.0 throughout. Miconazole was still active in this system, but only if C. albicans was first incubated with the miconazole for 3 h at pH 7.0. Further lowering of the pH, to below pH 5.5, reduced the growth enhancement that was seen and blocked the in vitro activity of miconazole (2) . The higher MIC at 48 h may therefore be primarily due to the prolongation of incubation required for sufficient growth of some yeasts, and as is known with bacteria, longer incubation times during susceptibility testing often leads to a higher MIC. Rapid growth in our microtiter test system permits the results of most susceptibility tests for C. albicans to be read at 24 h.
One difficulty that we encountered in all four of our test methods with fluconazole was the presence of a trailing endpoint. When testing azoles, a trailing endpoint manifested by a gradual decrease in growth rather than a clear, distinct endpoint inhibition of growth in tubes or wells is often observed (11, 15) . The lack of an exact endpoint has the potential to make the fungal susceptibility test results difficult to interpret. As noted, we found that a higher buffer concentration and a 48-h incubation time increase the likelihood that an isolate will demonstrate a trailing endpoint. This was particularly true for the microtiter panels. Espinel-Ingroff et al. (6) found a good correlation of the results between the tentative NCCLS test method and their microdilution test at 24 h when the full NCCLS-recommend MOPS buffer concentration was used. However, they used a nearly 10-fold higher inoculum in the microdilution tests (1 ϫ 10 4 CFU/ml) than that which they used in the macrodilution method (0.6 ϫ 10 3 to 2.1 ϫ 10
Determining the true susceptibilities of these strains is problematic. Eight of the nine isolates in question were from archived specimens collected before 1992. This was the year when significant azole use began at our institution. Since C. albicans, unlike C. krusei, is not intrinsically resistant to fluconazole, the majority of these isolates tested would be expected to be susceptible to fluconazole (9) . Additionally, our nine strains were tested by other investigators by a flow cytometric method that found, on the basis of an interpretation obtained with the 50% lethal dose for each strain, that the isolates were all susceptible to fluconazole at levels ranging from 0.2 to 3.0 g/ml (1). The mean level of sensitivity was 1.1 g/ml, and the mode was 1.1 g/ml (1). This correlation, along with the technically useful reduction of a trailing endpoint, supports the use of a 0.0165 M MOPS buffer concentration and the use of a 24-h incubation time for broth microdilution susceptibility testing of C. albicans whenever sufficient growth in the positive control well is present. Whether changes to the buffer concentration and incubation time should be considered for the broth macrodilution test is unclear, but further investigation of such changes is warranted. Our data, plus those from previous studies, indicate that the currently recommended MOPS concentration also leads to higher than expected MICs by the broth macrodilution method.
On the basis of the results of this investigation and our positive experience with continued clinical use of the described microdilution technique, we recommend that ongoing enhancements to the current NCCLS method be sought. The enhancements facilitate readable test results for most yeast isolates at 24 h and ensure that the methodology used does not artificially raise the MICs of important azole antifungal agents. Lowering of the MOPS buffer concentration to 0.0165 M may be a useful modification of the currently proposed NCCLS method.
